Argen-X (ARGX) - Total Assets
Based on the latest financial reports, Argen-X (ARGX) holds total assets worth €8.68 Billion EUR (≈ $10.15 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ARGX total equity for net asset value and shareholders' equity analysis.
Argen-X - Total Assets Trend (2010–2025)
This chart illustrates how Argen-X's total assets have evolved over time, based on quarterly financial data.
Argen-X - Asset Composition Analysis
Current Asset Composition (December 2025)
Argen-X's total assets of €8.68 Billion consist of 79.5% current assets and 20.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 40.2% |
| Accounts Receivable | €1.66 Billion | 19.1% |
| Inventory | €473.59 Million | 5.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €272.14 Million | 3.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Argen-X's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Argen-X.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Argen-X's current assets represent 79.5% of total assets in 2025, a decrease from 97.0% in 2010.
- Cash Position: Cash and equivalents constituted 40.2% of total assets in 2025, down from 85.6% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 19.1% of total assets.
Argen-X Competitors by Total Assets
Key competitors of Argen-X based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Allakos Inc
NASDAQ:ALLK
|
USA | $59.55 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
USA | $460.00 Million |
|
Youcare Pharmaceutical Group Co. Ltd. A
SHG:688658
|
China | CN¥5.19 Billion |
|
MoonLake Immunotherapeutics
NASDAQ:MLTX
|
USA | $424.43 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Argen-X - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.23 | 7.29 | 6.26 |
| Quick Ratio | 4.87 | 6.66 | 6.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €5.58 Billion | €4.07 Billion | €1.73 Billion |
Argen-X - Advanced Valuation Insights
This section examines the relationship between Argen-X's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.68 |
| Latest Market Cap to Assets Ratio | 4.80 |
| Asset Growth Rate (YoY) | 40.0% |
| Total Assets | €8.68 Billion |
| Market Capitalization | $41.72 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Argen-X's assets at a significant premium (4.80x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Argen-X's assets grew by 40.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Argen-X (2010–2025)
The table below shows the annual total assets of Argen-X from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €8.68 Billion ≈ $10.15 Billion |
+40.00% |
| 2024-12-31 | €6.20 Billion ≈ $7.25 Billion |
+36.55% |
| 2023-12-31 | €4.54 Billion ≈ $5.31 Billion |
+44.93% |
| 2022-12-31 | €3.13 Billion ≈ $3.66 Billion |
+9.96% |
| 2021-12-31 | €2.85 Billion ≈ $3.33 Billion |
+25.04% |
| 2020-12-31 | €2.28 Billion ≈ $2.66 Billion |
+41.56% |
| 2019-12-31 | €1.61 Billion ≈ $1.88 Billion |
+143.35% |
| 2018-12-31 | €661.70 Million ≈ $773.60 Million |
+48.70% |
| 2017-12-31 | €444.98 Million ≈ $520.23 Million |
+300.02% |
| 2016-12-31 | €111.24 Million ≈ $130.05 Million |
+121.37% |
| 2015-12-31 | €50.25 Million ≈ $58.75 Million |
-29.37% |
| 2014-12-31 | €71.15 Million ≈ $83.18 Million |
+105.99% |
| 2013-12-31 | €34.54 Million ≈ $40.38 Million |
+50.63% |
| 2012-12-31 | €22.93 Million ≈ $26.81 Million |
-28.21% |
| 2011-12-31 | €31.94 Million ≈ $37.34 Million |
+160.50% |
| 2010-12-31 | €12.26 Million ≈ $14.33 Million |
-- |
About Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develo… Read more